News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2013 Archives

Nov 19, 2013

Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for...

More
Nov 13, 2013

Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment...

More
Nov 7, 2013

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2013. Cash and investments in marketable securities at September 30, 2013 were...

More
Oct 30, 2013

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2013 on Thursday, November 7, 2013, after the close of U.S.-based financial...

More
Oct 24, 2013

Nektar Therapeutics (NASDAQ:NKTR) and Roswell Park Cancer Institute (RPCI) announced today that the first patients have been dosed in a phase II investigator-sponsored study of etirinotecan pegol...

More
Oct 8, 2013

Nektar Therapeutics (Nasdaq: NKTR) will present an overview of the company's proprietary drug candidate pipeline during the company's R&D Day for investors and analysts today from 11:30 a.m. to...

More
Oct 2, 2013

Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Tuesday, October 8, 2013 from 11:30 a.m. to 4:30 p.m. ET in...

More
Sep 30, 2013

Nektar Therapeutics (NASDAQ:NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an...

More
Sep 26, 2013
Company to Host Conference Call on Thursday, September 26th at 1:30 PM Pacific Time/4:30 PM Eastern Time to Discuss Results

Nektar Therapeutics (Nasdaq: NKTR) announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis...

More
Aug 8, 2013

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2013. Cash and investments in marketable securities at June 30, 2013 were $226.9...

More
Aug 1, 2013

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2013 on Thursday, August 8, 2013, after the close of U.S.-based financial markets....

More
Jul 30, 2013
-Recruitment Completed Five Months Ahead of Schedule-

Nektar Therapeutics (NASDAQ:NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer. The Phase 3...

More
Jun 19, 2013
NKTR-181 rates similar to placebo on "drug liking" and "feeling high" scores at all doses studied and differentiates from the widely abused drug oxycodone with high statistical significance (p<0.0001)

Nektar Therapeutics (Nasdaq: NKTR) today announced positive top-line results from a human abuse liability (HAL) study for NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of...

More
Jun 3, 2013
NKTR-214 Demonstrates Improved Efficacy and Better Tolerability in Aggressive and Resistant Preclinical Melanoma Model

Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, an investigational cancer immunotherapy which targets the IL-2 receptor complex and is being developed as a...

More
Jun 1, 2013

Nektar Therapeutics (NASDAQ:NKTR) announced today that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of...

More
May 30, 2013

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 Jefferies Global Healthcare Conference in New York at the...

More
May 16, 2013

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the...

More
May 9, 2013

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2013. Cash and investments in marketable securities at March 31, 2013 were $261.2...

More
May 2, 2013

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, after the close of U.S.-based financial markets. Howard...

More
Apr 7, 2013
NKTR-214 Demonstrates Improved Efficacy in Resistant Preclinical Melanoma Model Through Preferential Activation of Tumor Killing Immune Cell Subtype

Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association...

More
Mar 1, 2013

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve, is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the...

More
Feb 28, 2013

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2012. Cash, cash equivalents, and investments at December 31, 2012 were...

More
Feb 26, 2013

AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related...

More
Feb 13, 2013

Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2012 on Thursday, February 28, 2013, after the close of U.S.-based...

More
Feb 5, 2013

Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The study is being...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide